Ähnliche Pins
J&J Announces Plan to Spin Off DePuy Synthes
Johnson & Johnson World Headquarters, 1 Johnson and Johnson Plaza, New Brunswick, New Jersey 08933, United StatesJohnson & Johnson…
BESTÄTIGT90 % SICHERHEITvor 344 TagenThe release is datelined "NEW BRUNSWICK, NJ, October 14, 2025 - Johnson & Johnson ... today announced the Company's intent to separate its Orthopaedics business"; it states no time of day (CNBC's[3] report was up at 6:29 a.m. EDT and J&J's X post at 6:40 a.m. EDT), so the pin is the all-day 14 October.Johnson & Johnson said it would separate its roughly $9.2 billion-a-year orthopaedics business into a standalone company called DePuy Synthes within 18 to 24 months, and named former Smith & Nephew chief Namal Nawana to run it.0.66Lilly Agrees to Acquire Merida Biosciences for Up to $2.875 Billion
BESTÄTIGT88 % SICHERHEITvor 23 TagenThe release is datelined "INDIANAPOLIS and CAMBRIDGE, Mass., Aug. 31, 2026" and says the companies "today announced a definitive agreement for Lilly to acquire Merida".[1]Lilly agrees to buy Merida Biosciences, whose Phase 1 MER511 is built to destroy the autoantibodies behind Graves' disease and thyroid eye disease, for up to $2.875 billion in cash.$2.9B0.66J&J Proposes $5.5 Billion Deal to Settle 76,000 Ovarian Cancer Talc Claims
BESTÄTIGT82 % SICHERHEITvor 58 TagenJ&J's release is datelined "New Brunswick, N.J. - JULY 27, 2026 - Johnson & Johnson (NYSE: JNJ[1]) ... today announced", and the copy filed as Exhibit 99.1 to its 8-K is marked "FOR RELEASE AT 6:15PM ET", 22:15 UTC in EDT.Johnson & Johnson announced a proposed resolution of its remaining ovarian talc litigation, about 76,000 claims, with a $5.5 billion commitment paid per claim - no more than $3 billion in 2027 and nothing more before 2028 - if at least 95% of claimants take part.$5.5B0.66Oshkosh Acquires Pierce Manufacturing for $156.9 Million
BESTÄTIGT85 % SICHERHEITvor 30 JahrenOshkosh's own SEC[3] Form 10-K states the company acquired Pierce's stock for cash on September 18, 1996.Oshkosh Truck Corporation bought fire apparatus builder Pierce Manufacturing outright, a deal that kicked off Oshkosh's diversification and set up Pierce to become the world's largest fire truck maker.0.64DePuy Synthes trennt sich von Johnson & Johnson
GESCHÄTZT71 % SICHERHEITin 281 TagenDas 10-Q von J&J für das am 28. Juni 2026 endende Quartal strebt einen „Abschluss innerhalb von 18 bis 24 Monaten nach der ursprünglichen Ankündigung" vom 14. Oktober 2025 an (Mitte April bis Mitte Oktober 2027), und Finanzchef Joseph Wolk sagte im Juli, J&J sei „auf Kurs für eine Trennung Mitte 2027" (Bloomberg); „Mitte 2027" wird als Jahresmitte, also 1. Juli 2027, gelesen, was innerhalb dieses Zeitfensters liegt.[1]Das Orthopädiegeschäft von Johnson & Johnson soll als DePuy Synthes aus dem Konzern ausscheiden – per steuerfreiem Spin-off oder per Verkauf, wobei Apollo über rund 20 Milliarden Dollar verhandelt. J&J sieht sich auf Kurs für eine Trennung Mitte 2027.0.64J&J Enterprise Business Review (Investor Day)
GEPLANT85 % SICHERHEITin 76 TagenJ&J set the date itself: CFO Joseph Wolk said on the 15 July Q2 call "We look forward to sharing more on strategy, growth catalysts and a longer-term outlook at our Enterprise business review on December 8", and the source[1] reports he "expects to present stronger growth expectations at its Dec. 8 investor day"; no time or venue has been announced, so the pin sits at J&J's headquarters as an all-day date.Johnson & Johnson holds its first enterprise business review since December 2023, where CFO Joseph Wolk says it will set out growth above its 5% to 7% long-term target, with a clear line of sight to double digits by the end of the decade.0.64Abbott schließt Übernahme von Exact Sciences ab
BESTÄTIGT87 % SICHERHEITvor 184 TagenDie Mitteilung trägt die Ortsmarke "ABBOTT PARK, Ill., 23. März 2026 /PRNewswire/ -- Abbott (NYSE: ABT) gab heute bekannt, die Übernahme von Exact Sciences abgeschlossen zu haben".[1]Abbott hat den Barkauf des Cologuard-Herstellers Exact Sciences zu 105 Dollar je Aktie abgeschlossen; das Unternehmen ist nun eine hundertprozentige Abbott-Tochter. Die Exact-Sciences-Aktie wurde zuletzt am 20. März an der Nasdaq gehandelt.0.64Apollo in Talks to Buy J&J's DePuy Synthes for About $20 Billion
Johnson & Johnson World Headquarters, 1 Johnson and Johnson Plaza, New Brunswick, New Jersey 08933, United States
BESTÄTIGT82 % SICHERHEITvor 12 TagenThe disclosure is Bloomberg's report, dated "September 11, 2026" (Yahoo's[1][2][5] syndicated copy went up at 22:26 UTC and quotes Friday's closing share prices); Reuters' write-up the same evening says "Bloomberg News reported on Friday", and Quartz's 14 September story is a follow-up, so the pin is the all-day 11 September.Bloomberg reported that Apollo Global Management is in talks to buy DePuy Synthes, J&J's $9.3 billion-a-year orthopaedics unit, at a value close to $20 billion, with a deal possible within weeks though J&J could still spin the unit off instead.$20B0.63J&J Q2 2026 Results: $25.3B Sales, 2026 Outlook Raised
Johnson & Johnson World Headquarters, 1 Johnson and Johnson Plaza, New Brunswick, New Jersey 08933, United States
BESTÄTIGT83 % SICHERHEITvor 70 TagenConfirmed by J&J's release dated "New Brunswick, N.J. (July 15, 2026)", which says it "will conduct a conference call with investors to discuss this earnings release today at 8:30 a.m., Eastern Time" (12:30 UTC; the edited transcript is stamped "JULY 15, 2026 / 12:30PM GMT").[1]Johnson & Johnson reported second-quarter sales of $25.3 billion, up 6.6%, and adjusted EPS of $2.90, and raised its 2026 outlook to about $101.1 billion in sales and $11.68 adjusted EPS at the midpoint.0.63J&J Third-Quarter 2026 Results and Investor Call
Johnson & Johnson World Headquarters, 1 Johnson and Johnson Plaza, New Brunswick, New Jersey 08933, United States
GEPLANT73 % SICHERHEITin 20 TagenScheduled by J&J's 31 August release: it "will host a conference call for investors at 8:30 a.m. (Eastern Time) on Tuesday, October 13th to review third-quarter results" and "The press release will be available at approximately 6:45 a.m. (Eastern Time) the morning of the conference call"; 8:30 a.m. EDT is 12:30 UTC.[1]Johnson & Johnson releases its third-quarter 2026 results at about 6:45 a.m. Eastern on Tuesday 13 October and reviews them on an 8:30 a.m. investor call hosted by CEO Joaquin Duato and CFO Joseph Wolk.0.62J&J Signs a Drug-Pricing Deal With Trump and Joins TrumpRx
Johnson & Johnson World Headquarters, 1 Johnson and Johnson Plaza, New Brunswick, New Jersey 08933, United States
BESTÄTIGT86 % SICHERHEITvor 258 TagenJ&J's release is datelined "New Brunswick, N.J. – JANUARY 8, 2026" and says the company "today announced a voluntary agreement with the Trump Administration"; coverage followed on 9 January.[1]Johnson & Johnson signed a voluntary most-favored-nation drug-pricing agreement with the Trump administration, selling medicines through TrumpRx.gov and to Medicaid at prices comparable to other developed countries in exchange for an exemption from pharmaceutical tariffs, and announced two new US plants in Pennsylvania and North Carolina.0.62Abbott Agrees to Buy Exact Sciences for $21 Billion
BESTÄTIGT86 % SICHERHEITvor 307 TagenThe release is datelined "ABBOTT PARK, Ill., and MADISON, Wis., Nov. 20, 2025 /PRNewswire/ -- Abbott (NYSE: ABT) and Exact Sciences (NASDAQ: EXAS) today announced a definitive agreement".[1]Abbott agreed to buy Cologuard maker Exact Sciences for $105 a share in cash, a total equity value of about $21 billion, to enter cancer screening and precision oncology diagnostics.$21B0.62
